Yuderleys Masias-Leon

Yuderleys Masias-Leon

Auto-generated profile, based on publicly available information

Yuderleys Masias-Leon

Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMedha Singh
Medha Singh
MSMona O. Sarhan
Mona O. Sarhan
NDNerketa N. L. Damiba
Nerketa N. L. Damiba
ASAlok K. Singh
Alok K. Singh
AVAndres Villabona-Rueda
Andres Villabona-Rueda
SJSanjay Jain
Sanjay Jain
Mycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis. Here, we demonstrate that navitoclax, an orally bioavailable, small-molecule Bcl-2 inhibitor, significantly improves pulmonary tuberculosis (TB) treatments as a host-directed therapy. Addition of navitoclax to standard TB treatments at human equipotent dosing in mouse models of TB, inhibits Bcl-2 expression, leading to improved bacterial clearance, reduced tissue necrosis, fibrosis and decreased extrapulmonary bacterial dissemination. Using immunohistochemistry and flow cytometry, we show that navitoclax induces apoptosis in several immune cells, including CD68+ and CD11b+ cells. Finally, positron emission tomography (PET) in live animals using clinically translatable biomarkers for apoptosis (18F-ICMT-11) and fibrosis (18F-FAPI-74), demonstrates that navitoclax significantly increases apoptosis and reduces fibrosis in pulmonary tissues, which are confirmed in postmortem analysis. Our studies suggest that proapoptotic drugs such as navitoclax can potentially improve pulmonary TB treatments, reduce lung damage / fibrosis and may be protective against post-TB lung disease.

10 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CRCarlos E. Ruiz-Gonzalez
Carlos E. Ruiz-Gonzalez
ONOscar J. Nino-Meza
Oscar J. Nino-Meza
MSMedha Singh
Medha Singh
YMYuderleys Masias-Leon
Yuderleys Masias-Leon
AKAmy Kronenberg
Amy Kronenberg
SJSanjay Jain
Sanjay Jain
Invasive mold infections are a major cause of mortality in immunosuppressed and cancer patients. Diagnosis is challenging, requiring invasive procedures or reliance on fungal biomarkers with limited sensitivity and an inability to detect non-Aspergillus molds. Here, we perform whole-body 18F-fluorodeoxysorbitol (18F-FDS) positron emission tomography (PET) in nine prospectively enrolled patients with high-suspicion of invasive mold infections (eventually confirmed using culture or molecular assays, n = 4) or other pathologies (n = 5) with localization of 18F-FDS PET signal to infection sites as the primary outcome (NCT05611892). 18F-FDS PET (120 or 180 min after injection), rapidly detects and localizes invasive pulmonary and cerebral infections due to Aspergillus, non-Aspergillus (galactomannan-negative), or azole-resistant molds, and differentiates them from sterile inflammation or cancer. Moreover, 18F-FDS selectively and rapidly accumulates intracellularly in a range of clinically relevant molds, including azole-resistant molds, via a saturable process. In animals, 18F-FDS PET is able to detect and localize pulmonary and cerebral aspergillosis, as well as rhinosinusal infections due to Aspergillus, Rhizopus, and Mucor, confirming the clinical data. 18F-FDS can be easily synthesized from 18F-fluorodeoxyglucose (18F-FDG), which is widely available, and represents a promising, noninvasive diagnostic tool for detecting, localizing and monitoring of invasive mold infections throughout the body.

10 February 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
XCXueyi Chen
Xueyi Chen
CRCarlos E Ruiz-Gonzalez
Carlos E Ruiz-Gonzalez
YMYuderleys Masias-Leon
Yuderleys Masias-Leon
MSMedha Singh
Medha Singh
ONOscar J Nino-Meza
Oscar J Nino-Meza
SJSanjay Jain
Sanjay Jain
Tuberculous meningitis (TB meningitis), the most severe form of tuberculosis, carries high mortality and neurological sequelae, and current rifampin-based regimen are limited by poor central nervous system penetration. Alternative rifamycins like rifapentine and rifabutin, with different pharmacokinetic profiles, are effective for treating drug-susceptible pulmonary tuberculosis, with rifapentine now forming the basis of a World Health Organization-approved 4-month daily rifapentine-moxifloxacin regimen, and retrospective studies showing that rifabutin-based regimens are effective and well tolerated, however, both drugs still need dedicated evaluation in TB meningitis. Mice were intracranially inoculated with Mycobacterium tuberculosis and treated with rifamycin (rifampin, rifapentine, or rifabutin)-based regimens at human equipotent doses. We assessed the bactericidal activities of the 3 regimens, rifamycin tissue concentrations, brain inflammation (brain magnetic resonance imaging, tissue immunofluorescence, cytokines), and neuronal injury. Both rifapentine- and rifabutin-containing regimens demonstrated bactericidal activity in the brain, similar to or better than the standard rifampin-containing regimen, as well as reduced neuroinflammation and brain injury. Alternate rifamycins, rifapentine and rifabutin, show therapeutic activity and neuroprotective effects, supporting their evaluation in clinical trials for treating TB meningitis.

25 April 2023 in Revista Médicas UIS
Verified
Journal Article
Open access
KHKatherine Tatiana Centeno Hurtado
Katherine Tatiana Centeno Hurtado
DBDiego Fernando García Bohórquez
Diego Fernando García Bohórquez
YLYuderleys Masías León
Yuderleys Masías León
CGCarlos Eduardo Ruiz González
Carlos Eduardo Ruiz González
JVJuan Daniel Criado Villamizar
Juan Daniel Criado Villamizar
JRJavier Enrique Fajardo Rivero
Javier Enrique Fajardo Rivero
Introducción: la enfermedad pulmonar obstructiva crónica es una limitación del flujo de aire por anomalías alveolares. En una exacerbación aguda, la ventilación mecánica no invasiva es la primera línea en el manejo, sin embargo, existen ciertos factores de riesgo que hacen más probable el uso de ventilación mecánica invasiva en estos pacientes, que no están apropiadamente descritos en la literatura científica y que pueden guiar hacia una elección de soporte ventilatorio apropiado. Objetivo: describir los factores que se asociaron con mayor necesidad de ventilación mecánica no invasiva en una cohorte de pacientes hospitalizados con exacerbación aguda de la enfermedad pulmonar obstructiva crónica. Métodos: estudio observacional analítico de corte transversal, con muestreo no probabilístico que incluye todos los pacientes que consultaron a urgencias y fueron hospitalizados por exacerbación aguda de la enfermedad pulmonar obstructiva crónica en un hospital de tercer nivel de Santander, Colombia, durante el período 2014-2020. Resultados: fueron incluidos 81 pacientes, 36 requirieron ventilación mecánica no invasiva y 12 ventilación mecánica invasiva; 25 % de los pacientes con ventilación mecánica no invasiva fallaron a la terapia inicial y demandaron el uso de ventilación mecánica invasiva. Las comorbilidades más frecuentes fueron hipertensión arterial (70,3 %) y cardiopatía (49,38 %); 70 % había tenido exposición al tabaquismo como fumador directo. Conclusiones: el uso de ventilación mecánica invasiva estuvo relacionado de forma estadísticamente significativa en pacientes con perfil de disnea severa, acidosis por parámetros gasométricos, escalamiento antibiótico, uso de corticoides intravenosos, requerimiento de unidad de cuidado intensivo, infecciones asociadas al cuidado de la salud y estancia hospitalaria prolongada.

25 April 2023 in Revista Médicas UIS
Verified
Journal Article
Open access
KHKatherine Tatiana Centeno Hurtado
Katherine Tatiana Centeno Hurtado
DBDiego Fernando García Bohórquez
Diego Fernando García Bohórquez
YLYuderleys Masías León
Yuderleys Masías León
CGCarlos Eduardo Ruiz González
Carlos Eduardo Ruiz González
JVJuan Daniel Criado Villamizar
Juan Daniel Criado Villamizar
JRJavier Enrique Fajardo Rivero
Javier Enrique Fajardo Rivero
Introducción: la enfermedad pulmonar obstructiva crónica es una limitación del flujo de aire por anomalías alveolares. En una exacerbación aguda, la ventilación mecánica no invasiva es la primera línea en el manejo, sin embargo, existen ciertos factores de riesgo que hacen más probable el uso de ventilación mecánica invasiva en estos pacientes, que no están apropiadamente descritos en la literatura científica y que pueden guiar hacia una elección de soporte ventilatorio apropiado. Objetivo: describir los factores que se asociaron con mayor necesidad de ventilación mecánica no invasiva en una cohorte de pacientes hospitalizados con exacerbación aguda de la enfermedad pulmonar obstructiva crónica. Métodos: estudio observacional analítico de corte transversal, con muestreo no probabilístico que incluye todos los pacientes que consultaron a urgencias y fueron hospitalizados por exacerbación aguda de la enfermedad pulmonar obstructiva crónica en un hospital de tercer nivel de Santander, Colombia, durante el período 2014-2020. Resultados: fueron incluidos 81 pacientes, 36 requirieron ventilación mecánica no invasiva y 12 ventilación mecánica invasiva; 25 % de los pacientes con ventilación mecánica no invasiva fallaron a la terapia inicial y demandaron el uso de ventilación mecánica invasiva. Las comorbilidades más frecuentes fueron hipertensión arterial (70,3 %) y cardiopatía (49,38 %); 70 % había tenido exposición al tabaquismo como fumador directo. Conclusiones: el uso de ventilación mecánica invasiva estuvo relacionado de forma estadísticamente significativa en pacientes con perfil de disnea severa, acidosis por parámetros gasométricos, escalamiento antibiótico, uso de corticoides intravenosos, requerimiento de unidad de cuidado intensivo, infecciones asociadas al cuidado de la salud y estancia hospitalaria prolongada.

23 February 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
XCXueyi Chen
Xueyi Chen
CRCarlos E Ruiz-Gonzalez
Carlos E Ruiz-Gonzalez
YMYuderleys Masias-Leon
Yuderleys Masias-Leon
MSMedha Singh
Medha Singh
CPCharles A Peloquin
Charles A Peloquin
SJSanjay Jain
Sanjay Jain
Tuberculous meningitis causes substantial mortality due to limited penetration of antibiotics to the central nervous system and excessive neuroinflammation. This study evaluated clofazimine as an adjunct to the standard first-line tuberculosis regimen, in a mouse model. Mice were infected intracerebrally with Mycobacterium tuberculosis and treated for 6 weeks. Addition of clofazimine markedly reduced the brain bacterial burden, achieving measurable brain tissue concentrations despite minimal cerebrospinal fluid penetration, as well as attenuated brain tissue inflammation. These findings indicate that clofazimine enhances bactericidal activity of the standard regimen and mitigate neuroinflammation, supporting further investigation and clinical evaluation for tuberculous meningitis.